Mesoblast Limited · ASX:MSB
Mesoblast — Australian Biotech Summit (July 2005)
24 slides from Mesoblast's conference presentation, Jul 27, 2005
Slide 1: The Adult Stem Cell Company
The Adult Stem Cell Company Building Blocks for Better Health a pimesoblast
Slide 2: pmesoblast
pmesoblast
Slide 3: aS mesoblast
aS mesoblast
Slide 4: a mesoblast
a mesoblast in Vitra Tetipotent Blastocyst Fertilization Celis
Slide 5: pmesoblast
pmesoblast
Slide 6: A mesoblast
A mesoblast
Slide 7: Proprietary MPC Isolation
Slide 8: MPCs Give Rise To Various Tissue Types
MPCs Give Rise To Various Tissue Types: Potential Therapeutic Markets!
Slide 9: Multilineage Potential Of Human MPC
Multilineage Potential Of Human MPC Bone Fat Cartilage 1 2 3 4 2 3 1 £2 3 COLL~ dt vec el ood hoed cout ES CBFA- : pes PPARy2 | | i COLL-X om [|| on es LEPTIN | | le AGGN | | fm OCN Ce 1, Freshly isolated MPC PTH-F Ese 2. MPC cultured at wk 2 3. MPC cultured at wk 6, and differentiated IE ca: Ae (Oi
Slide 10: Human MPC Induce New Arterioles in Vivo
Human MPC Induce New Arterioles in Vivo cirect injection of 0.5x10° human MPC endothelium | VEGF-producing issue smooth muscle saline
Slide 11: a mesoblast
a mesoblast
Slide 12: Very Large, Unmet Cardiovascular Markets
Slide 13: can be used t
can be used t imited int
Slide 14: Sheep Models For Orthopaedic And Cardiovascular Conditions
Sheep Models For Orthopaedic And Cardiovascular Condition
Slide 15: My mesoblast
My mesoblast * 25-30% of the mid portion of the femur is resected. «Structural stability maintained by intramedullary ‘nal’ locked proximally and distally by transfixing screws.
Slide 16: MPC Therapy Causes Long-Term Bone Regeneration
Ley Ma mesoblast MPC Therapy Causes Long-Term Bone Regeneration CONTROL ANIMAL TEST ANIMAL TEST ANIMAL 6 months post- 6 months post- 12 months post- sham transplant MPC transplant MPC transplant
Slide 17: pmesoblast
pmesoblast
Slide 18: pimesoblast
pimesoblast
Slide 19: ay mesoblast
ay mesoblast
Slide 20: a mesoblast
a mesoblast
Slide 21: Milestone-Driven, Rapid Commercialisation
Milestone-Driven, Rapid Commercialisation si)
Slide 22: Clinical Studies
Clinical Studies Autologous __ Phase |b | open label Large Animal Studies (sheep) Allogeneic Jox/Efficacy FDA IND Approvals Allogeneic Phase Il Trials (randomised, controlled) Cardiovascular (1) heart attack _ (2) heart failure _ (3) bypass surgery Orthopedic bone fracture _ Spine fusion Orthopedic
Slide 23: Benefits of Initiating Human Clinical Trials Using Autologous Cells
Benefits of Initiating Human Clinical Trials Using Autologous Cells optimize ex vivo culture process improve cell engraftment and survival (e.g. matrix) identify appropriate clinical indications amenable to therapy determine optimal cell dose for safety/efficacy maintain careful registry of adverse
Slide 24: pmesoblast
pmesoblast